Olmesartan Medoxomil Accord

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Accord, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is used to manage high blood pressure in adult patients. GNH USA supplies Olmesartan Medoxil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps reduce systolic and diastolic blood pressure in adults. - Diabetic nephropathy: slows the progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve cardiac function and reduce hospitalisation risk.

Olmesartan Medoxil Accord may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness  - Headache  - Fatigue  - Nasal congestion  - Diarrhoea  - Upper respiratory tract infection 

Serious or Rare Side Effects: - Angio‑angry  - Hyper‑hyper  - Acute kidney injury  - Severe hypotension  - Liver enzyme elevation  - Myocardial infarction  - Bull‑t​  -   -   -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 

Olmesartan Medoxil Accord   g 

  t 

   t """"""""""""""""  """ """""" """ " " " """"""" "" " """ "" 

   g  t

   "  "